RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that certain
documents (the Proxy and the VIF) that have been mailed to shareholders in
connection with the 2013 annual general meeting to be held on June 19, 2013 at
9:00 a.m. EST (the "Meeting") contain an incorrect address for the location of
the Meeting. The correct location of the Meeting is The Sheraton Toronto Airport
Hotel & Conference Centre in the Spartan Room at 801 Dixon Road, Toronto,
Ontario M9W 1J5. 


The Company will not mail amended materials for the Meeting. Shareholders who
prefer not to vote via the internet or by proxy are welcome to attend the
Meeting in person. 


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada. 


At the date of this press release the Company had 13,571,195 shares issued and
outstanding. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. René C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024